The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...

The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep ...

Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep ...

The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

The U.S. Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

The fight against obstructive sleep apnea (OSA) has taken a monumental leap forward. For the first time, the U.S. Food and ...

Zepbound is Eli Lilly’s weight loss drug. Now, it is also a drug to treat obstructive sleep apnea (OSA).The U.S. Food and ...

Dec. 23, 2024 -- The FDA has approved the first prescription drug, Zepbound, for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity. Studies have shown that when ...

The new approval means that insurance providers will likely cover the medication for people with sleep apnea and obesity.

The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.